Innoviva Price to Book Ratio 2012-2026 | INVA
Historical price to book ratio values for Innoviva (INVA) over the last 10 years. The current price to book ratio for Innoviva as of September 07, 2026 is 1.26.
| Innoviva Price/Book Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | Book Value per Share | Price to Book Ratio |
| 2026-09-04 | 21.33 | 1.26 | |
| 2026-06-30 | 22.71 | $16.98 | 1.34 |
| 2026-03-31 | 23.30 | $18.18 | 1.28 |
| 2025-12-31 | 19.99 | $15.71 | 1.27 |
| 2025-09-30 | 18.25 | $13.51 | 1.35 |
| 2025-06-30 | 20.09 | $11.34 | 1.77 |
| 2025-03-31 | 18.13 | $10.31 | 1.76 |
| 2024-12-31 | 17.35 | $11.03 | 1.57 |
| 2024-09-30 | 19.31 | $10.68 | 1.81 |
| 2024-06-30 | 16.40 | $10.64 | 1.54 |
| 2024-03-31 | 15.24 | $11.21 | 1.36 |
| 2023-12-31 | 16.04 | $10.66 | 1.50 |
| 2023-09-30 | 12.99 | $9.75 | 1.33 |
| 2023-06-30 | 12.73 | $8.51 | 1.50 |
| 2023-03-31 | 11.25 | $8.53 | 1.32 |
| 2022-12-31 | 13.25 | $8.18 | 1.62 |
| 2022-09-30 | 11.61 | $9.19 | 1.26 |
| 2022-06-30 | 14.76 | $8.11 | 1.82 |
| 2022-03-31 | 19.35 | $7.93 | 2.44 |
| 2021-12-31 | 17.25 | $7.56 | 2.28 |
| 2021-09-30 | 16.71 | $7.08 | 2.36 |
| 2021-06-30 | 13.41 | $5.67 | 2.37 |
| 2021-03-31 | 11.95 | $6.87 | 1.74 |
| 2020-12-31 | 12.39 | $5.99 | 2.07 |
| 2020-09-30 | 10.45 | $5.28 | 1.98 |
| 2020-06-30 | 13.98 | $4.86 | 2.88 |
| 2020-03-31 | 11.76 | $4.01 | 2.94 |
| 2019-12-31 | 14.16 | $3.38 | 4.19 |
| 2019-09-30 | 10.54 | $2.80 | 3.76 |
| 2019-06-30 | 14.56 | $2.44 | 5.98 |
| 2019-03-31 | 14.03 | $1.98 | 7.10 |
| 2018-12-31 | 17.45 | $1.57 | 11.09 |
| 2018-09-30 | 15.24 | $-1.07 | -14.22 |
| 2018-06-30 | 13.80 | $-1.53 | -9.03 |
| 2018-03-31 | 16.67 | $-2.10 | -7.94 |
| 2017-12-31 | 14.19 | $-2.38 | -5.96 |
| 2017-09-30 | 14.12 | $-2.06 | -6.84 |
| 2017-06-30 | 12.80 | $-2.71 | -4.72 |
| 2017-03-31 | 13.83 | $-3.06 | -4.52 |
| 2016-12-31 | 10.70 | $-3.26 | -3.29 |
| 2016-09-30 | 10.99 | $-3.36 | -3.27 |
| 2016-06-30 | 10.53 | $-3.26 | -3.23 |
| 2016-03-31 | 12.59 | $-3.20 | -3.93 |
| 2015-12-31 | 10.54 | $-2.99 | -3.53 |
| 2015-09-30 | 7.18 | $-2.75 | -2.61 |
| 2015-06-30 | 17.74 | $-2.51 | -7.06 |
| 2015-03-31 | 15.21 | $-2.23 | -6.83 |
| 2014-12-31 | 13.52 | $-1.92 | -7.04 |
| 2014-09-30 | 16.04 | $-1.68 | -9.57 |
| 2014-06-30 | 27.65 | $-1.66 | -16.70 |
| 2014-03-31 | 23.15 | $2.34 | 9.89 |
| 2013-12-31 | 26.67 | $2.68 | 9.94 |
| 2013-09-30 | 30.57 | $2.99 | 10.24 |
| 2013-06-30 | 28.82 | $0.85 | 33.91 |
| 2013-03-31 | 17.67 | $0.92 | 19.17 |
| 2012-12-31 | 16.64 | $1.58 | 10.56 |
| 2012-09-30 | 19.38 | $1.77 | 10.94 |
| 2012-06-30 | 16.62 | $1.95 | 8.51 |
| 2012-03-31 | 14.59 | $0.07 | 205.74 |
| 2011-12-31 | 16.53 | $-1.02 | -16.25 |
| 2011-09-30 | 15.07 | $-0.69 | -21.68 |
| 2011-06-30 | 16.61 | $-0.44 | -37.57 |
| 2011-03-31 | 18.12 | $-0.33 | -54.52 |
| 2010-12-31 | 18.75 | $-0.28 | -67.22 |
| 2010-09-30 | 15.04 | $-1.91 | -7.88 |
| 2010-06-30 | 9.40 | $-1.71 | -5.50 |
| 2010-03-31 | 9.96 | $-1.55 | -6.44 |
| 2009-12-31 | 9.78 | $-2.94 | -3.32 |
| 2009-09-30 | 10.95 | $-2.76 | -3.97 |
| 2009-06-30 | 10.95 | $-2.52 | -4.34 |
| 2009-03-31 | 12.72 | $-2.30 | -5.53 |
| 2008-12-31 | 9.27 | $-2.18 | -4.26 |
| 2008-09-30 | 9.32 | $-2.02 | -4.61 |
| 2008-06-30 | 8.88 | $-1.82 | -4.89 |
| 2008-03-31 | 7.88 | $-1.48 | -5.31 |
| 2007-12-31 | 14.59 | $-1.08 | -13.45 |
| 2007-09-30 | 19.52 | $-0.67 | -29.05 |
| 2007-06-30 | 23.94 | $-0.26 | -91.86 |
| 2007-03-31 | 22.07 | $0.34 | 65.37 |
| 2006-12-31 | 23.11 | $1.05 | 21.95 |
| 2006-09-30 | 20.23 | $1.57 | 12.90 |
| 2006-06-30 | 17.12 | $2.10 | 8.15 |
| 2006-03-31 | 20.98 | $2.65 | 7.91 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.541B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1081.958B | 36.50 |
| Johnson & Johnson (JNJ) | United States | $663.276B | 25.34 |
| AbbVie (ABBV) | United States | $453.112B | 23.59 |
| Merck (MRK) | United States | $370.890B | 46.83 |
| Roche Holding AG (RHHBY) | Switzerland | $350.157B | 0.00 |
| Novartis AG (NVS) | Switzerland | $305.285B | 18.43 |
| Novo Nordisk (NVO) | Denmark | $208.069B | 11.59 |
| Pfizer (PFE) | United States | $162.156B | 9.33 |
| Sanofi (SNY) | France | $107.257B | 9.03 |
| Bayer (BAYRY) | Germany | $55.767B | 9.92 |